» Authors » Johann Poetzl

Johann Poetzl

Explore the profile of Johann Poetzl including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 89
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Guerrieri D, Horvat M, Fan J, Wang J, Lemke L, von Richter O, et al.
Bioanalysis . 2023 Nov; 16(1):33-48. PMID: 38031738
The antidrug antibody (ADA) signal-to-noise (S/N) ratio was explored as a novel immunogenicity measure to evaluate the immune response of healthy subjects to a single dose of GP2017, an adalimumab...
12.
Pan L, Mora J, Walravens K, Wagner L, Hopper S, Loo L, et al.
Bioanalysis . 2023 Aug; 15(14):773-814. PMID: 37526071
The 2022 16th Workshop on Recent Issues in Bioanalysis (WRIB) took place in Atlanta, GA, USA on September 26-30, 2022. Over 1000 professionals representing pharma/biotech companies, CROs, and multiple regulatory...
13.
Loo L, Harris S, Milton M, Meena , Lembke W, Berisha F, et al.
Bioanalysis . 2022 May; 14(11):737-793. PMID: 35578991
The 15th edition of the Workshop on Recent Issues in Bioanalysis (15th WRIB) was held on 27 September to 1 October 2021. Even with a last-minute move from in-person to...
14.
Hersey S, Keller S, Mathews J, King L, Bandukwala A, Berisha F, et al.
Bioanalysis . 2022 May; 14(10):627-692. PMID: 35578974
The 15th edition of the Workshop on Recent Issues in Bioanalysis (15th WRIB) was held on 27 September to 1 October 2021. Even with a last-minute move from in-person to...
15.
Corsaro B, Yang T, Murphy R, Sonderegger I, Exley A, Bertholet S, et al.
Bioanalysis . 2021 Feb; 13(6):415-463. PMID: 33533276
The 14 edition of the Workshop on Recent Issues in Bioanalysis (14 WRIB) was held virtually on June 15-29, 2020 with an attendance of over 1000 representatives from pharmaceutical/biopharmaceutical companies,...
16.
Smolen J, Cohen S, Tony H, Scheinberg M, Kivitz A, Balanescu A, et al.
Rheumatology (Oxford) . 2020 Jul; 60(1):256-262. PMID: 32699904
Objectives: This report provides data for the extent of B cell depletion and recovery, efficacy, safety and immunogenicity of Sandoz rituximab (SDZ-RTX; GP2013; Rixathon®) compared with reference rituximab (Ref-RTX) up...
17.
von Richter O, Lemke L, Haliduola H, Fuhr R, Koernicke T, Schuck E, et al.
Expert Opin Biol Ther . 2019 Jan; 19(10):1075-1083. PMID: 30698045
: To compare the pharmacokinetics of Sandoz biosimilar adalimumab (GP2017) with reference adalimumab (Humira) in healthy volunteers (PK similarity study) and to compare the pharmacokinetics of GP2017 administered by autoinjector...
18.
Matucci-Cerinic M, Allanore Y, Kavanaugh A, Buch M, Schulze-Koops H, Kucharz E, et al.
RMD Open . 2018 Nov; 4(2):e000757. PMID: 30487998
Objectives: To demonstrate the equivalent efficacy and compare the safety and immunogenicity of an etanercept biosimilar, GP2015, with reference etanercept (ETN) in patients with moderate-to-severe, active rheumatoid arthritis (RA), characterised...
19.
von Richter O, Skerjanec A, Afonso M, Sanguino Heinrich S, Poetzl J, Woehling H, et al.
Br J Clin Pharmacol . 2016 Oct; 83(4):732-741. PMID: 27790726
Aims: To assess pharmacokinetics (PK) and safety of GP2015, a proposed etanercept biosimilar, in two studies: comparison with etanercept originator (ETN, bioequivalence study) and comparison of GP2015 administered via an...